# Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

> **NCT03183570** · EARLY_PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 21 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Primary Sclerosing Cholangitis
- Covid19 Pneumonia

## Interventions

- **DRUG:** [18F]FP-R01-MG-F2

## Key facts

- **NCT ID:** NCT03183570
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-08
- **Primary completion:** 2023-04-25
- **Final completion:** 2025-01-25
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03183570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03183570, "Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03183570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*